Celon Pharma (LTS:0RKX) 3-1 Month Momentum %: N/A% (As of Aug. 23, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0RKX Celon Pharma SA LTS:0RKX
19 GF Score
Price zł22.50
! 4 Warning Signs
View Full Analysis

What is Celon Pharma 3-1 Month Momentum %?

Celon Pharma LTS:0RKX 19 3-1 Month Momentum % is N/A% as of Aug. 23, 2026. GuruFocus rates LTS:0RKX with a GF Score™ of 19/100. The stock has 4 warning signs investors should review. Among 1,021 Drug Manufacturers companies, Celon Pharma ranks better than 60.82% on this metric.

3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-23), Celon Pharma's 3-1 Month Momentum % is N/A%.

The industry rank for Celon Pharma's 3-1 Month Momentum % or its related term are showing as below:

LTS:0RKX's 3-1 Month Momentum % is not ranked *
in the Drug Manufacturers industry.
Industry Median: -3.95
* Ranked among companies with meaningful 3-1 Month Momentum % only.

Celon Pharma  (LTS:0RKX) 3-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Celon Pharma 3-1 Month Momentum % Related Terms

LTS:0RKX vs ZTS, UTHR, VTRS: 3-1 Month Momentum % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Celon Pharma's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Celon Pharma 3-1 Month Momentum % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Celon Pharma's 3-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Celon Pharma's 3-1 Month Momentum % falls into.


LTS:0RKX
19GF Score
Celon Pharma SA LTS:0RKX
3-1 Month Momentum % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Celon Pharma  (LTS:0RKX) 3-1 Month Momentum % Calculation

3-1 Month Momentum % is calculated as following:

3-1 Month Momentum %=( Price 1-month ago / Price 3-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 3-1 Month Momentum % →
What does a 3-1 Month Momentum % of N/A% mean?
Celon Pharma (LTS:0RKX) has a 3-1 Month Momentum % of N/A% as of Aug. 23, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Celon Pharma and its competitors. According to the industry distribution chart, Celon Pharma ranks #400 out of 1021 companies in the Drug Manufacturers industry, placing it in the top 39.2%.
Is Celon Pharma's 3-1 Month Momentum % too high?
Celon Pharma's current 3-1 Month Momentum % is N/A%. Based on the distribution chart, Celon Pharma ranks #400 out of 1021 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Celon Pharma has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Celon Pharma's 3-1 Month Momentum % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Celon Pharma ranks #400 out of 1021 companies for 3-1 Month Momentum %. This puts Celon Pharma in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Drug Manufacturers company?
A good 3-1 Month Momentum % depends on the Drug Manufacturers industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Celon Pharma and its competitors. Celon Pharma's current 3-1 Month Momentum % is N/A%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celon Pharma stock overvalued right now?
Celon Pharma (LTS:0RKX) has a current 3-1 Month Momentum % of N/A%. The current 3-1 Month Momentum % is N/A%. Celon Pharma's overall GF Score™ is 19/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Celon Pharma (LTS:0RKX), the current 3-1 Month Momentum % is N/A% as of Aug. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Celon Pharma Business Description

Other Exchanges CLN:Poland8RP:Germany
Address Ogrodowa 2A, Kielpin, Lomianki, POL, 05-092
Celon Pharma SA is a Poland based company engages in the research of therapeutic solutions and development, production, distribution, and marketing of specialized generic products. It invests in the development of innovative pharmaceuticals with potential applications in the treatment of cancer, neurological diseases, diabetes and other metabolic disorders. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir, and Valzek, as well as inhalation powder.
19GF Score

Get the complete analysis for LTS:0RKX

3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł22.50
Price